A 6-week ketogenic diet in treatment-resistant depression: a prospective single-arm feasibility pilot trial
Frontiers in Nutrition · 22.07.2026 · 13
DOI: 10.3389/fnut.2026.1870412 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Nutrition, online erschienen am 22.07.2026. Verfasst von Cemre Cukaci und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical-Scientific Fund of the Mayor of the Federal Capital Vienna.
Themen: Depression
Abstract (Originalsprache)
Background
Prior evidence for the ketogenic diet (KD) interventions in treatment-resistant depression (TRD) was very limited when recruitment for the present pilot trial began on 1 November 2023. This pilot trial aimed to examine feasibility, adherence, safety, and preliminary clinical signals in patients with TRD treated with a 6-week KD intervention.
Methods
This prospective, single-arm, open-label pilot trial was conducted in adult patients with TRD who had a baseline Montgomery-Åsberg Depression Rating Scale (MADRS) score of at least 20. The intervention consisted of a 6-week KD; preexisting psychopharmacological treatment had to be stable before study entry and was not changed during the intervention. Adherence was monitored by daily fasting capillary β -hydroxybutyrate measurements. The MADRS was assessed at baseline and after 2, 4, and 6 weeks in all participants. A response was defined as a ≥ 50% reduction in the MADRS score from baseline; remission was defined as a MADRS score of ≤10.
Results
A total of 13 eligible patients were offered study participation; 5 declined, and 8 were enrolled. Four patients completed the full 6-week intervention. One patient discontinued after week 2, one patient was excluded after a revised diagnosis, and two patients discontinued because nutritional ketosis was not achieved. Nutritional ketosis was documented in all completers and was accompanied by marked symptomatic improvement in three of the four completers. Among the completers, two patients met the remission criteria at week 6, whereas one showed partial improvement and one showed no relevant antidepressant benefit despite sustained nutritional ketosis. The intervention was generally feasible, but recruitment and retention were challenging.
Conclusion
In this small prospective pilot trial, a KD was feasible in a subset of patients with TRD and was associated with improvement in depressive symptoms in three of the four completers. However, recruitment difficulties, early discontinuations, and heterogeneity of clinical responses highlight the need for larger controlled studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
- Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.
- Department of Psychiatry and Psychotherapeutic Medicine, University Hospital St. Pölten, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria.
Förderung
- Medical-Scientific Fund of the Mayor of the Federal Capital Vienna
Zitieren
APA
Cukaci, C., Rabl, U., & Frey, R. (2026). A 6-week ketogenic diet in treatment-resistant depression: a prospective single-arm feasibility pilot trial. Frontiers in Nutrition, 13. https://doi.org/10.3389/fnut.2026.1870412
Vancouver
Cukaci C, Rabl U, Frey R. A 6-week ketogenic diet in treatment-resistant depression: a prospective single-arm feasibility pilot trial. Frontiers in Nutrition. 2026;13. doi:10.3389/fnut.2026.1870412
BibTeX
@article{Cukaci2026,
author = {Cukaci, Cemre and Rabl, Ulrich and Frey, Richard},
title = {A 6-week ketogenic diet in treatment-resistant depression: a prospective single-arm feasibility pilot trial},
journal = {Frontiers in Nutrition},
year = {2026},
volume = {13},
doi = {10.3389/fnut.2026.1870412}
}
EUVIMED